Vanguard Health Care ETF

VHT

Market cap $18.1B

Market jitters return on fresh U.S.-Iran tensions. Energy, dividend, low-volatility and defensive ETFs could help investors navigate renewed uncertainty.

Big pharma's patent cliff risk is somewhat overstated, as layered IP and litigation often extend exclusivity beyond headline expiries. Incremental innovation—new formulations, improved delivery, and higher dosing—effectively extends product lifecycles and drives shareholder value.

The Vanguard Health Care Index Fund ETF Shares (VHT) was launched on January 26, 2004, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market.

The Vanguard Health Care ETF offers a significantly lower expense ratio than the VanEck Pharmaceutical ETF. The VanEck Pharmaceutical ETF has a higher concentration and higher trailing returns, while the Vanguard Health Care ETF provides broader sector diversification across more than 400 holdings.

Healthcare ETFs are gaining attention as Middle East tensions and market volatility boost demand for defensive sectors.

LLY's $4B vaccine push is boosting interest in healthcare ETFs like IHE with heavy exposure to the drugmaker.

U.S.-Iran tensions rise as Hormuz risks grow. Markets turn volatile -- dividend, low-beta, and defensive ETFs may help cushion portfolios.

Investors are questioning the staying power of medical technology (medtech) stocks, which have fallen from grace since the COVID-19 pandemic. The starting point is to distinguish between medtech and other healthcare industries.

Goldman lifts UnitedHealth's target price, spotlighting ETFs like IHF as diversified ways to tap its growth while cushioning Medicaid-driven risks.

Recent White House and FDA actions fast-track psychedelic depression drug approvals, granting priority review vouchers and accelerating rescheduling for eligible therapies. Compass Pathways leads with a CNPV for COMP360 in treatment-resistant depression, positive Phase 3 data, and a sub-$1bn market cap suggesting potential upside.